Risk of High-grade skin rash in cancer patients treated with cetuximab - An antibody against epidermal growth factor receptor: Systemic review and Meta-analysis

Oncology

Volumn 77, Issue 2, 2008, Pages 124-133

  Su, Xiao ^a   Lacouture, Mario E ^b   Jia, Yuxia ^c   Wu, Shenhong ^c  

^a AtlantiCare   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Stony Brook Medicine   (United States)

Author keywords

Antibody; Cancer; Cetuximab; Epidermal growth factor receptor; Side effect; Skin rash

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; IRINOTECAN;

ACNE; ADVANCED CANCER; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DESQUAMATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; ESOPHAGUS CANCER; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDICAL SOCIETY; META ANALYSIS; NEOPLASM; OVARY CANCER; OVERALL SURVIVAL; PAIN; PERITONEUM CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK; RISK FACTOR; SALIVARY GLAND CANCER; SKIN TOXICITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ULCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; EXANTHEMA; HUMANS; INCIDENCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK;

EID: 67650702948     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000229752     Document Type: Review

References (53)

1. Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G: Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol 2007; 39: 1416-1431.
2. Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H, Matsushita N: Membrane-anchored growth factors, the epider-mal growth factor family: beyond receptor ligands. Cancer Sci 2008; 99: 214-220.
3. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS: Epider-mal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2-16.
4. Ritter CA, Arteaga CL: The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 2003; 30: 3-11.
5. Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, Holcmann M: The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2007; 75: 770-787.
6. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Holscher AH, Danenberg PV: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7: 1850-1855.
7. Galizia G, Lieto E, Ferraraccio F, De Vita F, Castellano P, Orditura M, Imperatore V, La Mura A, La Manna G, Pinto M, Catalano G, Pignatelli C, Ciardiello F: Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 2006; 13: 823-835.
8. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
9. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002; 94: 1593-1611.
10. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799.
11. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP: Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6: 4874-4884. (Pubitemid 32110432)
12. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing or-thotopically in nude mice. Clin Cancer Res 1999; 5: 257-265.
13. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345. (Pubitemid 38944402)
14. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ: Phase II trial of ce-tuximab in patients with refractory colorec-tal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
15. Souglakos J, Kalykaki A, Vamvakas L, An-droulakis N, Kalbakis K, Agelaki S, Vardakis N, Tzardi M, Kotsakis AP, Gioulbasanis J, Tsetis D, Sfakiotaki G, Chatzidaki D, Mav-roudis D, Georgoulias V: Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxali-platin-based chemotherapy. Ann Oncol 2007; 18: 305-310.
16. Jonker DJ, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ: Ce-tuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048.
17. Folprecht G, Lutz MP, Schoffski P, Seuffer-lein T, Nolting A, Pollert P, Kohne CH: Ce-tuximab and irinotecan/5-fluorouracil/fo-linic acid is a safe combination for the first-line treatment of patients with epider-mal growth factor receptor expressing meta-static colorectal carcinoma. Ann Oncol 2006; 17: 450-456.
18. Tabernero J, Van Cutsem E, Diaz-Rubio E, Cervantes A, Humblet Y, Andŕ T, Van Laet-hem JL, Soulie P, Casado E, Verslype C, Va-lera JS, Tortora G, Ciardiello F, Kisker O, de Gramont A: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25: 5225-5232.
19. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Yous-soufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
20. Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, Pfeifer W, O'Byrne KJ, Welte T, Kolb R, Pirker R, Che-maissani A, Perol M, Ranson MR, Ellis PA, Pilz K, Reck M: Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann On-col 2008; 19: 362-369.
21. Burtness B: The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 2005: 1085-1093. (Pubitemid 41170037)
22. Lordick F, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Röthling N, Fend F, Peschel C: Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final re- CJ, Karapetis sults from a multicenter phase II study of the AIO upper GI Study Group. 2007 ASCO Annu Meet Proc. J Clin Oncol 2007; 25: 4526.
23. Lacouture ME, Melosky BL: Cutaneous reactions to anticancer agents targeting the epi-dermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett 2007; 12: 1-5.
24. Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann On-col 2005; 16: 1425-1433.
25. Perez-Soler R, Saltz L: Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23: 5235-5246.
26. NCI: Common terminology criteria for adverse events (CTCAE) of National Cancer Institute 2006, http://ctep.cancer.gov/reporting/ctc-archive.html.
27. Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Janne PA, Bonomi P: Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006; 24: 5253-5258.
28. Pessino A, Artale S, Sciallero S, Guglielmi A, Fornarini G, Andreotti IC, Mammoliti S, Comandini D, Caprioni F, Bennicelli E, An-dretta V, Siena S, Sobrero A: First-line single-agent cetuximab in patients with advanced colorectal cancer. Ann Oncol 2008; 19: 711-716.
29. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/ or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-2177.
30. Gold PJ, Goldman B, Iqbal S, Leichman LP, Lenz HJ, Blanke CD: Cetuximab as second-line therapy in patients with metastatic esophageal cancer: A phase II Southwest Oncology Group Study. J Clin Oncol 2008; 26: 222s (abstr 4536).
31. Gruenwald V, Wilkens L, Gebel M, Wirth T, Greten T, Kubicka S, Manns MP, Ganser A, Malek NP: A phase II open-label study of ce-tuximab in unresectable hepatocellular carcinoma. 2006 ASCO Annu Meet Proc. J Clin Oncol 2006; 24: 14079.
32. Lenz HJ, Mayer RJ, Mirtsching B, Cohn AL, Pippas A, Windt P, Cutsem Ev: Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. 2005 ASCO Annu Meet Proc. J Clin Oncol 2005; 23: 3536.
33. Licitra LF, Locati LD, Potepan P, Crippa F, Bossi P, Bergamini C, Rinaldi G, Liberatosci-oli C, Perrone F, Losa M, Pilotti S: Cetux-imab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCS): a monoinstitutional phase II study. 2006 ASCO Annu Meet Proc. J Clin Oncol 2006; 24: 5547.
34. Maubec E, Petrow P, Duvillard P, Certain A, Duval X, Kerob D, Bagot M, Faivre S, Mentŕ F, Avril M: Cetuximab as first-line mono-therapy in patients with unresectable squamous cell carcinoma of the skin: Preliminary results of a phase II multicenter study. J Clin Oncol 2008; 26:493s (abstr 9042).
35. Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain JF, C, Michotte A, Greve JD: A multicenter stratified phase II study of cetuximab for the treatment of patients with recurrent high-grade glioma. 2008 ASCO Annu Meet Proc. J Clin Oncol 2008; 26: 2017.
36. Schilder RJ, Lokshin AE, Holloway RW, Alvarez RD, Pathak H, Aghajanian C, Drescher CW, Godwin AK: Phase II trial of single-agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. 2007 ASCO Annu Meet Proc. J Clin Oncol 2007; 25: 5577.
37. Wierzbicki R, Jonker DJ, Moore MJ, Berry SR, Loehrer PJ, Fox F, Katz T, Rowinsky EK, Youssoufian H: A phase II multicenter study of cetuximab monotherapy in patients with EGFR-undetectable refractory metastatic colorectal carcinoma (MCRC). J Clin Oncol 2008; 26:194s (abstr 4065).
38. Zhu AX, Blaszkowsky L, Enzinger PC, Bhar-gava P, Ryan DP, Meyerhardt J, Horgan K, Hale K, Sheehan S, Stuart K: Phase II study of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma. 2006 ASCO Annu Meet Proc. J Clin Oncol 2006; 24: 14096.
39. Nanney LB, Stoscheck CM, King LE Jr, Underwood RA, Holbrook KA: Immunolocal-ization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990; 94: 742-748.
40. Jost M, Kari C, Rodeck U: The EGF receptor - an essential regulator of multiple epi-dermal functions. Eur J Dermatol 2000; 10: 505-510.
41. Lacouture ME: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803-812.
42. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD: Wild-type KRAS is required for panitu-mumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
43. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S: KRAS wild-type state predicts survival and is associated to early radiological response in meta-static colorectal cancer treated with cetux-imab. Ann Oncol 2008; 19: 508-515.
44. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-1169.
45. Lièvre A, Bachet JB, Le Corre D, Boige V, L, Chaskis Landi B, Emile JF, Côt́ JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
46. Karapetis CS, Khambata-Ford S, Jonker DJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
47. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC: Randomized double-blind trial of prophylactic oral minocycline and topical taz-arotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25: 5390-5396.
48. Davies JM, Goldberg RM: First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park) 2008; 22: 1470-1479;discussion 1479-1483.
49. Giusti RM, Shastri K, Pilaro AM, Fuchs C, Cordoba-Rodriguez R, Koti K, Rothmann M, Men AY, Zhao H, Hughes M, Keegan P, Weiss KD, Pazdur R: US Food and Drug Administration approval: Panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 2008; 14: 1296-1302.
50. Saif MW, Cohenuram M: Role of panitu-mumab in the management of metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6: 118-124.
51. Cartwright TH, Genther R: Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer. Clin Colorectal Cancer 2008; 7: 202-203.
52. Heun J, Holen K: Treatment with panitu-mumab after a severe infusion reaction to ce-tuximab in a patient with metastatic colorec-tal cancer: A case report. Clin Colorectal Cancer 2007; 6: 529-531.
53. Saif MW, Peccerillo J, Potter V: Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: Report of three cases and review of literature. Cancer Chemother Pharmacol 2009; 63: 1017-1022.